Cargando…
Outpatient parenteral antimicrobial therapy (OPAT) in patients with cystic fibrosis
BACKGROUND: To determine complications during outpatient parenteral antimicrobial therapy (OPAT) administrated through a peripheral venous line, PICC-line or PORT-A-CATH (PAC). METHODS: Catheter related complications in patients with cystic fibrosis during OPAT were identified through a retrospectiv...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4515313/ https://www.ncbi.nlm.nih.gov/pubmed/26212271 http://dx.doi.org/10.1186/s12879-015-1019-4 |
_version_ | 1782382895431680000 |
---|---|
author | Pedersen, Maya Graham Jensen-Fangel, Søren Olesen, Hanne Vebert Tambe, San deep Prataprao Petersen, Eskild |
author_facet | Pedersen, Maya Graham Jensen-Fangel, Søren Olesen, Hanne Vebert Tambe, San deep Prataprao Petersen, Eskild |
author_sort | Pedersen, Maya Graham |
collection | PubMed |
description | BACKGROUND: To determine complications during outpatient parenteral antimicrobial therapy (OPAT) administrated through a peripheral venous line, PICC-line or PORT-A-CATH (PAC). METHODS: Catheter related complications in patients with cystic fibrosis during OPAT were identified through a retrospective review of patient files supplemented by an interview. RESULTS: In 64 treatment episodes with a peripheral venous line, 51 (79.7 %) used bolus injection and 13 (20.3 %) used infusion pump. 27 out of 51 (53.0 %) bolus injection episodes experienced complications, which required removal. None were observed for infusion pump treatments. The infectious complications requiring removal of peripheral venous line were 9 out of 23 (39.1 %) for the PICC line and 11 out of 26 (42.3 %) for the PAC. No anaphylaxis was observed during the OPAT treatments. CONCLUSIONS: Our data indicate that using an infusion pump to administer the antibiotic treatment minimized peripheral venous line complications. The frequency of complications leading to removal of the catheter is about the same for PICC-lines and PACs, but the average life-time of the latter is much longer. Allergic reactions are not a major problem. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-015-1019-4) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4515313 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-45153132015-07-27 Outpatient parenteral antimicrobial therapy (OPAT) in patients with cystic fibrosis Pedersen, Maya Graham Jensen-Fangel, Søren Olesen, Hanne Vebert Tambe, San deep Prataprao Petersen, Eskild BMC Infect Dis Research Article BACKGROUND: To determine complications during outpatient parenteral antimicrobial therapy (OPAT) administrated through a peripheral venous line, PICC-line or PORT-A-CATH (PAC). METHODS: Catheter related complications in patients with cystic fibrosis during OPAT were identified through a retrospective review of patient files supplemented by an interview. RESULTS: In 64 treatment episodes with a peripheral venous line, 51 (79.7 %) used bolus injection and 13 (20.3 %) used infusion pump. 27 out of 51 (53.0 %) bolus injection episodes experienced complications, which required removal. None were observed for infusion pump treatments. The infectious complications requiring removal of peripheral venous line were 9 out of 23 (39.1 %) for the PICC line and 11 out of 26 (42.3 %) for the PAC. No anaphylaxis was observed during the OPAT treatments. CONCLUSIONS: Our data indicate that using an infusion pump to administer the antibiotic treatment minimized peripheral venous line complications. The frequency of complications leading to removal of the catheter is about the same for PICC-lines and PACs, but the average life-time of the latter is much longer. Allergic reactions are not a major problem. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-015-1019-4) contains supplementary material, which is available to authorized users. BioMed Central 2015-07-27 /pmc/articles/PMC4515313/ /pubmed/26212271 http://dx.doi.org/10.1186/s12879-015-1019-4 Text en © Pedersen et al. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Pedersen, Maya Graham Jensen-Fangel, Søren Olesen, Hanne Vebert Tambe, San deep Prataprao Petersen, Eskild Outpatient parenteral antimicrobial therapy (OPAT) in patients with cystic fibrosis |
title | Outpatient parenteral antimicrobial therapy (OPAT) in patients with cystic fibrosis |
title_full | Outpatient parenteral antimicrobial therapy (OPAT) in patients with cystic fibrosis |
title_fullStr | Outpatient parenteral antimicrobial therapy (OPAT) in patients with cystic fibrosis |
title_full_unstemmed | Outpatient parenteral antimicrobial therapy (OPAT) in patients with cystic fibrosis |
title_short | Outpatient parenteral antimicrobial therapy (OPAT) in patients with cystic fibrosis |
title_sort | outpatient parenteral antimicrobial therapy (opat) in patients with cystic fibrosis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4515313/ https://www.ncbi.nlm.nih.gov/pubmed/26212271 http://dx.doi.org/10.1186/s12879-015-1019-4 |
work_keys_str_mv | AT pedersenmayagraham outpatientparenteralantimicrobialtherapyopatinpatientswithcysticfibrosis AT jensenfangelsøren outpatientparenteralantimicrobialtherapyopatinpatientswithcysticfibrosis AT olesenhannevebert outpatientparenteralantimicrobialtherapyopatinpatientswithcysticfibrosis AT tambesandeepprataprao outpatientparenteralantimicrobialtherapyopatinpatientswithcysticfibrosis AT peterseneskild outpatientparenteralantimicrobialtherapyopatinpatientswithcysticfibrosis |